Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly. More: After AbbVie and Genmab's ph.
read moreWith Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilm’s group CEO reflected on the unit’s unique facility design philosophy and how it’s eschewing big M&A plays to expand in-house. More: JPM26: Fujifilm CEO touts biologics
read moreFor the fourth year running—and the third in a row for Skyrizi specifically—an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings. More: AbbVie’s Skyrizi takes full-year TV ad spending crown yet again,
read moreExelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big. More: Single-drug Exelixis aims to be
read more© 1994 - 2026 B.M. Pharmaceuticals